pyruvaldehyde and Kidney Diseases

pyruvaldehyde has been researched along with Kidney Diseases in 13 studies

Pyruvaldehyde: An organic compound used often as a reagent in organic synthesis, as a flavoring agent, and in tanning. It has been demonstrated as an intermediate in the metabolism of acetone and its derivatives in isolated cell preparations, in various culture media, and in vivo in certain animals.
methylglyoxal : A 2-oxo aldehyde derived from propanal.

Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.

Research

Studies (13)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Aortal Pulse Wave Velocity (aPWV)

Aortal pulse wave velocity is measured by a non-invasive oscillometric device. (NCT02095873)
Timeframe: Week 0 and Week 8 (first intervention); Week 14 and Week 22 (second intervention)

Area Under the Curve for Oral Glucose Tolerance Test (oGGT)

A standard 75 g glucose oGTT will be performed, as routinely used in clinical practice. Participants will be instructed to eat carbohydrate rich diet (> 150 g/day) for at least three days before the test, followed by an overnight fast. Participants will be instructed to have comparable macronutrient composition of the dinner before the respective study days in the metabolic unit. During the oGTT both capillary and venous blood samples will be collected after 0, 15, 30, 60, 90 and 120 min. To minimize the inconvenience of repeated blood tests during the oGTT, a venous cannula will be inserted, under sterile conditions, prior to the test, for blood sampling. (NCT02095873)
Timeframe: Week 0 and Week 8 (first intervention); Week 14 and Week 22 (second intervention)

Finger-fold Capillary Density by Capillaroscopy

After 20 min seated at rest, measurements are made with the subject seated and the left hand at heart level. Nail-fold capillaries in the dorsal skin of the third finger are visualized using a stereo microscope linked to a monochrome digital camera. Capillary density is defined as the number of capillaries per mm2 of nail-fold skin and is computed as the mean of 4 measurements. (NCT02095873)
Timeframe: Week 0 and Week 8 (first intervention); Week 14 and Week 22 (second intervention)

Flow-mediated Dilatation (FMD)

Brachial artery FMD will be assessed. Ultrasound imaging of the brachial artery will be performed. Percent FMD will be calculated using the averaged minimum mean brachial artery diameter at baseline compared to the largest mean values obtained after either release of the forearm occlusion. (NCT02095873)
Timeframe: Week 0 and Week 8 (first intervention); Week 14 and Week 22 (second intervention)

Reviews

2 reviews available for pyruvaldehyde and Kidney Diseases

Other Studies

11 other studies available for pyruvaldehyde and Kidney Diseases